BCL2L1 and wet macular degeneration: Additionally, UNITY Biotechnology, a startup that develops therapeutics against aging with a focus on senescence, has been conducting clinical trials of senolytic Bcl-xL inhibitor UBX1325 in patients with diabetic macular edema (DME) and wet age-related macular degeneration (wet AMD) [102,103].